Clinical Trial Record

Return to Clinical Trials

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients


2003-01


2013-09


2013-09


329

Study Overview

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a standard care program in improving end-of-life care in patients with advanced lung , gastrointestinal, genitourinary, or breast cancer.

OBJECTIVES: * Determine the efficacy of an early intervention palliative care program comprising a phone-based nurse educator and shared medical appointments in improving end-of-life care of patients with advanced lung, gastrointestinal, genitourinary, or breast cancer. * Compare symptom management, quality of life, and the match between preference of care and the care received in patients treated with an early intervention palliative care program vs a standard care program. * Compare health care utilization by patients treated with these interventions. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to cancer diagnosis (lung vs breast vs gastrointestinal vs genitourinary) and participating center. Patients are randomized to 1 of 2 intervention arms. * Arm I (early-intervention palliative care program): Patients complete the Medical Care Questionnaire and receive a computer-generated prescription letter that outlines the problems they have identified; the patient's physician also receives a copy of the letter. Patients receive a series of phone calls weekly for 4 weeks and then at least monthly from a nurse educator. The phone calls address 3 major areas: coordination of palliative care options in the cancer center and the patient's community, including referrals for psychological or spiritual counseling, social work consultation, financial guidance, home health, palliative care or hospice services, and bereavement counseling for the family; problem-solving therapy, focusing on the identification of problems, definition of achievable goals, a plan for reaching those goals, and evaluation of success; and tailored psycho-educational modules from Ȭharting Your Course", covering end-of-life topics such as symptom management, advanced care planning, communication with the health care team and family members, spirituality, and nutrition. Patients also receive information regarding the purpose and time/location of symptom management, shared medical appointments (SMAs), which they can attend in person or call in to participate via speaker phone. SMAs are 1.5-hour monthly sessions conducted by a physician and a nurse practitioner that can accommodate 10-12 patients and their caregivers. The sessions include a welcome/social period, a question and answer/peer discussion, an interactive educational session, and an opportunity for one-on-one nurse practitioner appointments with a focus on a brief review of the patients' medical treatment plans. * Arm II (standard palliative care program): Patients receive standard palliative care from their physician/nurse practitioner team and have access to the palliative care nurse at the discretion of the treating physician. Patients complete Functional Assessment of Chronic Illness Therapy-Palliative Care at baseline and every 3 months thereafter. Patients and caregivers complete surveys measuring their perception of the quality of the patient's cancer care at baseline and at 1 month. A caregiver or family member completes the After-Death Bereaved Family Member Interview to evaluate the adequacy of patient care at 3 months post-patient death. PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study.

  • Cancer
  • OTHER: counseling intervention
  • OTHER: educational intervention
  • PROCEDURE: psychosocial assessment and care
  • PROCEDURE: quality-of-life assessment
  • CDR0000452966
  • R01CA101704 (U.S. NIH Grant/Contract)
  • P30CA023108 (U.S. NIH Grant/Contract)
  • DMS-0226
  • DMS-CPHS-16004

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2005-11-11  

N/A  

2014-12-18  

2005-11-11  

N/A  

2014-12-19  

2005-11-15  

N/A  

2014-12  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Supportive Care


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: ENABLE (concurrent palliative care)

telephone based ENABLE educational intervention

OTHER: counseling intervention

OTHER: educational intervention

PROCEDURE: psychosocial assessment and care

PROCEDURE: quality-of-life assessment

ACTIVE_COMPARATOR: Usual Care

Supportive and palliative usual care services at DHMC, Behavioral

OTHER: counseling intervention

PROCEDURE: psychosocial assessment and care

PROCEDURE: quality-of-life assessment

Primary Outcome MeasuresMeasure DescriptionTime Frame
Quality of life as measured by Functional Assessment of Cancer Therapy-Palliative care version (FACT-Pal) at baseline, one month, and every three months thereafterBaseline, one month, every three months
Symptom management as measured by Edmunton Symptom Assessment Scale at baseline, one month, and every three months thereafterBaseline, one month, every three months
Health care utilization by a chart review of days in hospital, ICU, ER visits at baseline, one month, and every three months thereafterBaseline, one month, every three months
Correlate preferences for care and care received as measured by After Death Bereaved Family Member Interview with a family member of the deceasedBaseline, one month, every three months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Depression as measured by Center for Epidemiological Studies-Depression (CES-D) at baseline, one month, and every three months thereafterBaseline, one month, every three months
Problem solving skills as measured by Social Problem-Solving Skills Inventory-revised at baseline and one monthBaseline, one month, every three months
Caregiver burden as measured by Montgomery-Borgatta Caregiver Burden Scale at baseline, one month, and every three months thereafter (given to caregivers of patients)Baseline, one month, every three months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    DISEASE CHARACTERISTICS:

  • Diagnosis of 1 of the following advanced cancers:


  • Stage IIIB or IV non-small cell lung cancer
  • Extensive stage small cell lung cancer
  • Stage IV breast cancer


  • Poor prognostic indicators (conferring likelihood of ≤ 2 years survival), including, but not limited to, any of the following:


  • Visceral crisis
  • Lung or liver metastasis
  • Estrogen receptor-negative disease
  • HER2/neu-positive disease
  • Progressive or recurrent disease during or within 2 years of first treatment
  • Unresectable stage III or stage IV gastrointestinal cancers
  • Stage IV genitourinary cancers


  • Prostate cancer must be hormone refractory
  • Hormone receptor status:


  • Not specified

  • PATIENT CHARACTERISTICS:
    Sex

  • Not specified

  • Menopausal status

  • Not specified

  • Performance status

  • Not specified

  • Life expectancy

  • Not specified

  • Hematopoietic

  • Not specified

  • Hepatic

  • Not specified

  • Renal

  • Not specified

  • Other

  • No dementia or significant confusion (i.e., Mini Mental Exam score < 25)
  • No Axis I psychiatric disorders (DSM-IV), including any of the following:


  • Schizophrenia
  • Bipolar disorder
  • Active substance use disorder

  • PRIOR CONCURRENT THERAPY:
    Endocrine therapy

  • See Disease Characteristics

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • National Cancer Institute (NCI)

  • PRINCIPAL_INVESTIGATOR: Marie A Bakitas, PhD, Norris Cotton Cancer Center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA. 2009 Aug 19;302(7):741-9. doi: 10.1001/jama.2009.1198.
  • Corn BW, Feldman DB, Hull JG, O'Rourke MA, Bakitas MA. Dispositional hope as a potential outcome parameter among patients with advanced malignancy: An analysis of the ENABLE database. Cancer. 2022 Jan 15;128(2):401-409. doi: 10.1002/cncr.33907. Epub 2021 Oct 6.
  • Prescott AT, Hull JG, Dionne-Odom JN, Tosteson TD, Lyons KD, Li Z, Li Z, Dragnev KH, Hegel MT, Steinhauser KE, Ahles TA, Bakitas MA. The role of a palliative care intervention in moderating the relationship between depression and survival among individuals with advanced cancer. Health Psychol. 2017 Dec;36(12):1140-1146. doi: 10.1037/hea0000544. Epub 2017 Oct 19.